This study aims to provide new insights into the RTKi resistance mechanisms caused by MED12 mutations in NSCLC, propose immediately applicable treatment strategies to overcome this resistance, and highlight the importance of MED12 as a companion diagnostic marker and therapeutic target. This evidence concerns the gene MED12 and non-small cell lung carcinoma.